Category 1 Testing is a relatively new discipline to assess the performance of abuse deterrent opioid formulations (ADF) with laboratory experiments. The FDA has issued Category 1 guidelines for branded and generic products in the past years. However, ADF technologies, regulatory expectations, and real world abuse techniques are evolving very rapidly and staying up-to-date is more important than ever before.
Register now and take this unique opportunity to…
This is a must-attend meeting for everyone involved in the development, manufacture, testing, and commercialization of abuse deterrent products.
We are looking forward to meeting you in June.
The hotel is across the street from the King Street metro station, providing easy access to Washington, DC.
10 min. from Washington National Airport
35 min. from Dulles International Airport
Agenda Day 1